Contraception
Volume 81, Issue 1 , Pages 89-90 , January 2010

Response to the Letter to the Editor

References 

  1. Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception. 2008;78:451–458
  2. Fleischer K, van Vliet HAAM, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res. 2009;123:429–435
  3. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427–1429
  4. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131–134
  5. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105:1114–1118

PII: S0010-7824(09)00306-0

doi: 10.1016/j.contraception.2009.06.004

Contraception
Volume 81, Issue 1 , Pages 89-90 , January 2010

Article Tools